A federal decide in Massachusetts shot down Janssen Biotech’s makes an attempt to restrict discovery in a qui tam motion, concluding that communications between workers and attorneys did not bar the pharmaceutical firm from having to show over lots of of paperwork that have been subsequently shared with third-party consultants.
Trending
- China Deals Dominate Largest APAC M&A in H1 With US Firm Leading
- Too much vitamin B6 can be toxic. 3 symptoms to watch out for | Food-wine News
- 2025 Class Action Settlements Already Top $21B, Keeping Pace With Record-Shattering Levels of Past 3 Years
- From Madurai to New York: Meet Semma’s chef Vijay Kumar, whose authentic Tamil cuisine is turning heads worldwide | Food-wine News
- Latham, Wachtell, Kirkland, Freshfields Lead Law Firm Midyear M&A Leagues, as Deal Value Climbs 33% From Last Year
- Should you get your pet sterilised? | Pets-animals News
- Whistleblower Complaint Leads to Awkward Disclosure for PetMed Express
- ‘Ozempic liya hai toh kya hua, ek zindagi jeeni hai…’: Ram Kapoor shares his controversial stance on weight loss medications | Health News
Saturday, July 5
Janssen Biotech Ordered to Turn Over Privileged Info Shared With Consultants, Judge Rules
